Reduced-port robot radical colorectal cancer surgery a prospective trial and standardized port strategy

Reduced-port robotic colorectal surgery minimizes trauma but faces technical challenges. We assessed the domestic BMR-5000 system in a standardized "3 + 1" configuration for radical colorectal cancer surgery. This prospective, single-arm trial used objective performance criteria.The surgical non-conversion rate served as the device efficacy endpoint; the primary safety endpoint was device-related Clavien-Dindo grade III or higher complications within 30 days.The technical feasibility and safety of the 3-port BMR-5000 approach served as the primary observational objective in the clinical implementation of this study. Of 60 patients, 40 underwent radical colorectal resections (23 rectal, 7 sigmoid, 6 right colectomy, 4 left colectomy). Non-conversion rate was 100% (95% exact CI 94.0-100.0), exceeding the 90% target. No device-related Clavien-Dindo grade III or higher complications occurred. Mean total operative time was 268.08 ± 84.75 min, mean estimated blood loss was 23.61 ± 27.88 mL, with no intraoperative transfusions. Mean postoperative length of stay was 9.77 ± 4.39 days. Pain scores decreased from 2.72 ± 1.58 perioperatively to 0.22 ± 0.45 by postoperative day 35. In cases requiring lymphadenectomy (n = 40), mean lymph node yield was 13.6 ± 2.97 Overall Clavien-Dindo grade I or higher complications occurred in 5 patients (8.3%); readmission, reoperation, and mortality within 30 days were 0. Reduced-port robot-assisted radical colorectal surgery with the BMR-5000 is feasible and safe, achieving 100% non-conversion, minimal blood loss, and favorable short-term outcomes. Larger comparative studies are warranted.